Works by Piha-Paul, Sarina A.

Results: 106
    1
    2
    3

    Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit.

    Published in:
    Oncology, 2017, v. 92, n. 1, p. 14, doi. 10.1159/000449505
    By:
    • Kinahan, Holly;
    • Maiti, abhishek;
    • Hess, Kenneth;
    • Dempsey, Jennifer;
    • Beatty, Laura;
    • Baldwin, Sarah;
    • Hong, David S.;
    • Naing, aung;
    • Fu, Siqing;
    • Tsimberidou, apostolia M.;
    • Piha-Paul, Sarina;
    • Janku, Filip;
    • Karp, Daniel;
    • Reddy, Suresh;
    • Yennu, Sriram;
    • Epner, Daniel;
    • Bruera, Eduardo;
    • Meric-Bernstam, Funda;
    • Falchook, Gerald;
    • Subbiah, Vivek
    Publication type:
    Article
    4

    Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion.

    Published in:
    Oncology, 2016, v. 91, n. 6, p. 348, doi. 10.1159/000449204
    By:
    • Subbiah, Vivek;
    • Holmes, Oliver;
    • Gowen, Kyle;
    • Spritz, Daniel;
    • amini, Behrang;
    • Wang, Wei-Lien;
    • Schrock, alexa B.;
    • Meric-Bernstam, Funda;
    • Zinner, Ralph;
    • Piha-Paul, Sarina;
    • Zarzour, Maria;
    • Elvin, Julia a.;
    • Erlich, Rachel L.;
    • Stockman, David L.;
    • Vergilio, Jo-anne;
    • Suh, James H.;
    • Stephens, Philip J.;
    • Miller, Vincent;
    • Ross, Jeffrey S.;
    • ali, Siraj M.
    Publication type:
    Article
    5

    First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.

    Published in:
    Oncologist, 2024, v. 29, n. 4, p. e514, doi. 10.1093/oncolo/oyad338
    By:
    • Piha-Paul, Sarina A;
    • Xu, Binghe;
    • Dumbrava, Ecaterina E;
    • Fu, Siqing;
    • Karp, Daniel D;
    • Meric-Bernstam, Funda;
    • Hong, David S;
    • Rodon, Jordi A;
    • Tsimberidou, Apostolia M;
    • Raghav, Kanwal;
    • Ajani, Jaffer A;
    • Conley, Anthony P;
    • Mott, Frank;
    • Fan, Ying;
    • Fan, Jean;
    • Peng, Peng;
    • Wang, Hui;
    • Ni, Shumao;
    • Sun, Caixia;
    • Qiang, Xiaoyan
    Publication type:
    Article
    6
    7

    Overview of Ocular Side Effects of Selinexor.

    Published in:
    Oncologist, 2021, v. 26, n. 7, p. 619, doi. 10.1002/onco.13756
    By:
    • Al‐Zubidi, Nagham;
    • Gombos, Dan S.;
    • Hong, David S.;
    • Subbiah, Vivek;
    • Fu, Siqing;
    • Ahnert, Jordi Rodon;
    • Piha‐Paul, Sarina A.;
    • Tsimberidou, Apostolia M.;
    • Karp, Daniel D.;
    • Bernstam, Funda Meric;
    • Naing, Aung
    Publication type:
    Article
    8
    9

    Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors.

    Published in:
    Oncologist, 2021, v. 26, n. 7, p. 558, doi. 10.1002/onco.13682
    By:
    • Tsimberidou, Apostolia‐Maria;
    • Vo, Henry Hiep;
    • Subbiah, Vivek;
    • Janku, Filip;
    • Piha‐Paul, Sarina;
    • Yilmaz, Bulent;
    • Gong, Jing;
    • Naqvi, Mohammad Faraz;
    • Tu, Shi‐Ming;
    • Campbell, Matthew;
    • Meric‐Bernstam, Funda;
    • Naing, Aung
    Publication type:
    Article
    10

    Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma.

    Published in:
    Liver Cancer (2235-1795), 2025, v. 14, n. 1, p. 58, doi. 10.1159/000540290
    By:
    • Abou-Alfa, Ghassan K.;
    • Meyer, Tim;
    • Do, Richard Kinh Gian;
    • Piha-Paul, Sarina A.;
    • Light, Joseph S.;
    • Sherrin, Scott;
    • Yaqubie, Amin;
    • O'Neill, Alison Clemens;
    • Harding, James J.;
    • Al-Rajabi, Raed;
    • Denlinger, Crystal S.;
    • Cano, Pablo;
    • Cornelius, Albert S.;
    • O'Reilly, Eileen M.;
    • DiPrimeo, Daniel;
    • Eli, Lisa D.;
    • Gordan, John D.;
    • Solit, David B.
    Publication type:
    Article
    11

    Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study.

    Published in:
    2019
    By:
    • George, Goldy C;
    • Iwuanyanwu, Eucharia C;
    • Buford, Adrianna S;
    • Piha-Paul, Sarina A;
    • Subbiah, Vivek;
    • Fu, Siqing;
    • Karp, Daniel D;
    • Pant, Shubham;
    • Hinojosa, Christina O;
    • Hess, Kenneth R;
    • Cleeland, Charles S;
    • Bernstam, Elmer V;
    • Meric-Bernstam, Funda;
    • Hong, David S
    Publication type:
    journal article
    12
    13
    14
    15
    16
    17
    18

    A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 2, p. 107, doi. 10.1007/s00280-023-04545-4
    By:
    • Piha-Paul, Sarina A.;
    • Tseng, Chieh;
    • Tran, Hai T.;
    • Gao, Meng;
    • Karp, Daniel D.;
    • Subbiah, Vivek;
    • Tsimberidou, Apostolia Maria;
    • Kawedia, Jitesh D.;
    • Fu, Siqing;
    • Pant, Shubham;
    • Yap, Timothy A.;
    • Morris, Van K.;
    • Kee, Bryan K.;
    • Blum Murphy, Mariela;
    • Lim, JoAnn;
    • Meric-Bernstam, Funda
    Publication type:
    Article
    19

    Pharmacokinetics and safety of niraparib in patients with moderate hepatic impairment.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2021, v. 88, n. 5, p. 825, doi. 10.1007/s00280-021-04329-8
    By:
    • Akce, Mehmet;
    • El-Khoueiry, Anthony;
    • Piha-Paul, Sarina A.;
    • Bacque, Emeline;
    • Pan, Peng;
    • Zhang, Zhi-Yi;
    • Ewesuedo, Reginald;
    • Gupta, Divya;
    • Tang, Yongqiang;
    • Milton, Ashley;
    • Zajic, Stefan;
    • Judson, Patricia L.;
    • O'Bryant, Cindy L.
    Publication type:
    Article
    20
    21
    22

    Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience.

    Published in:
    Cancer Medicine, 2016, v. 5, n. 12, p. 3437, doi. 10.1002/cam4.956
    By:
    • Wang, Zhijie;
    • Shi, Naiyi;
    • Naing, Aung;
    • Janku, Filip;
    • Subbiah, Vivek;
    • Araujo, Dejka M.;
    • Patel, Shreyaskumar R.;
    • Ludwig, Joseph A.;
    • Ramondetta, Lois M.;
    • Levenback, Charles F.;
    • Ramirez, Pedro T.;
    • Piha‐Paul, Sarina A.;
    • Hong, David;
    • Karp, Daniel D.;
    • Tsimberidou, Apostolia M.;
    • Meric‐Bernstam, Funda;
    • Fu, Siqing
    Publication type:
    Article
    23

    IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade.

    Published in:
    2017
    By:
    • Ayers, Mark;
    • Lunceford, Jared;
    • Nebozhyn, Michael;
    • Murphy, Erin;
    • Loboda, Andrey;
    • Kaufman, David R.;
    • Albright, Andrew;
    • Cheng, Jonathan D.;
    • Kang, S. Peter;
    • Shankaran, Veena;
    • Piha-Paul, Sarina A.;
    • Yearley, Jennifer;
    • Seiwert, Tanguy Y.;
    • Ribas, Antoni;
    • McClanahan, Terrill K.
    Publication type:
    journal article
    24
    25
    26
    27
    28
    29
    30

    Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.

    Published in:
    JNCI Cancer Spectrum, 2020, v. 4, n. 2, p. 1, doi. 10.1093/jncics/pkz093
    By:
    • Piha-Paul, Sarina A;
    • Hann, Christine L;
    • French, Christopher A;
    • Cousin, Sophie;
    • Braña, Irene;
    • Cassier, Phillippe A;
    • Moreno, Victor;
    • Bono, Johann S de;
    • Harward, Sara Duckworth;
    • Ferron-Brady, Geraldine;
    • Barbash, Olena;
    • Wyce, Anastasia;
    • Wu, Yuehui;
    • Horner, Thierry;
    • Annan, Meg;
    • Parr, Nigel J;
    • Prinjha, Rabinder K;
    • Carpenter, Christopher L;
    • Hilton, John;
    • Hong, David S
    Publication type:
    Article
    31

    Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial.

    Published in:
    Scientific Reports, 2022, v. 12, n. 1, p. 1, doi. 10.1038/s41598-022-16588-3
    By:
    • Mendoza, Tito R.;
    • Hong, David S.;
    • Peterson, Christine B.;
    • Stephen, Bettzy;
    • Dumbrava, Ecaterina;
    • Pant, Shubbam;
    • Tsimberidou, Apostolia Maria;
    • Yap, Timothy Anthony;
    • Sheshadri, Ajay;
    • Altan, Mehmet;
    • George, Goldy;
    • Castillo, Lilibeth;
    • Rodriguez, Enedelia;
    • Gong, Jing;
    • Subbiah, Vivek;
    • Janku, Filip;
    • Fu, Siqing;
    • Piha-Paul, Sarina A.;
    • Ahnert, Jordi Rodon;
    • Karp, Daniel D.
    Publication type:
    Article
    32
    33

    Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.

    Published in:
    Cancer (0008543X), 2024, v. 130, n. 3, p. 400, doi. 10.1002/cncr.35063
    By:
    • Knisely, Anne;
    • Ahmed, Jibran;
    • Stephen, Bettzy;
    • Piha‐Paul, Sarina A.;
    • Karp, Daniel;
    • Zarifa, Abdulrazzak;
    • Fu, Siqing;
    • Hong, David Sanghyun;
    • Rodon Ahnert, Jordi;
    • Yap, Timothy A.;
    • Tsimberidou, Apostolia M.;
    • Alshawa, Anas;
    • Dumbrava, Ecaterina E.;
    • Yang, Yali;
    • Song, Juhee;
    • Meric‐Bernstam, Funda;
    • Jazaeri, Amir A.;
    • Naing, Aung
    Publication type:
    Article
    34

    Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer.

    Published in:
    Cancer (0008543X), 2023, v. 129, n. 14, p. 2201, doi. 10.1002/cncr.34773
    By:
    • Nelson, Blessie Elizabeth;
    • Saleem, Sadia;
    • Damodaran, Senthil;
    • Somaiah, Neeta;
    • Piha‐Paul, Sarina;
    • Moore, Julia Ann;
    • Yilmaz, Bulent;
    • Ogbonna, Deby;
    • Karp, Daniel D.;
    • Dumbrava, Ecaterina;
    • Tsimberidou, Apostolia M.;
    • Hong, David S.;
    • Rodon Ahnert, Jordi;
    • Milton, Denái R.;
    • Zheng, Xiaofeng;
    • Booser, Daniel J.;
    • Ibrahim, Nuhad K.;
    • Conley, Anthony P.;
    • Bhosale, Priya;
    • Rojas Hernandez, Cristhiam M.
    Publication type:
    Article
    35

    Clinical activity of checkpoint inhibitors in angiosarcoma: A retrospective cohort study.

    Published in:
    2022
    By:
    • Ravi, Vinod;
    • Subramaniam, Aparna;
    • Zheng, Jing;
    • Amini, Behrang;
    • Trinh, Van A.;
    • Joseph, Jocelyn;
    • Mennel, Robert G.;
    • Bishop, Andrew J.;
    • Sturgis, Erich M.;
    • Goepfert, Ryan P.;
    • Yalamanchili, Sudha;
    • Botello, Gilberto;
    • Stephen, Bettzy;
    • Piha‐Paul, Sarina A.;
    • Patel, Anisha B.;
    • Lazar, Alexander J.;
    • Conley, Anthony P.;
    • Benjamin, Robert S.;
    • Patel, Shreyaskumar R.;
    • Futreal, Phillip A.
    Publication type:
    journal article
    36

    Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology.

    Published in:
    NPJ Precision Oncology, 2022, v. 6, n. 1, p. 1, doi. 10.1038/s41698-022-00317-0
    By:
    • Vo, Henry Hiep;
    • Fu, Siqing;
    • Hong, David S.;
    • Karp, Daniel D.;
    • Piha-Paul, Sarina;
    • Subbiah, Vivek;
    • Janku, Filip;
    • Naing, Aung;
    • Yap, Timothy A.;
    • Rodon, Jordi;
    • Ajani, Jaffer A.;
    • Cartwright, Carrie;
    • Johnson, Amber;
    • Song, I-Wen;
    • Beck, Jennifer;
    • Kahle, Michael;
    • Nogueras-Gonzalez, Graciela M.;
    • Miller, Vincent;
    • Chao, Calvin;
    • Vining, David J.
    Publication type:
    Article
    37

    Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study.

    Published in:
    NPJ Precision Oncology, 2021, v. 5, n. 1, p. 1, doi. 10.1038/s41698-021-00159-2
    By:
    • Tsimberidou, Apostolia Maria;
    • Hong, David S.;
    • Fu, Siqing;
    • Karp, Daniel D.;
    • Piha-Paul, Sarina;
    • Kies, Merrill S.;
    • Ravi, Vinod;
    • Subbiah, Vivek;
    • Patel, Sunil M.;
    • Tu, Shi-Ming;
    • Janku, Filip;
    • Heymach, John;
    • Johnson, Amber;
    • Cartwright, Carrie;
    • Zhao, Li;
    • Zhang, Jianhua;
    • Berry, Donald A.;
    • Vining, David J.;
    • Futreal, Andrew;
    • Miller, Vincent A.
    Publication type:
    Article
    38

    Analysis of MET Genetic Aberrations in Patients With Breast Cancer at MD Anderson Phase I Unit.

    Published in:
    Clinical Breast Cancer, 2014, v. 14, n. 6, p. 468, doi. 10.1016/j.clbc.2014.06.001
    By:
    • Debora, de Melo Gagliato;
    • Fontes Jardim, Denis L.;
    • Falchook, Gerald;
    • Tang, Chad;
    • Zinner, Ralph;
    • Wheler, Jennifer J.;
    • Janku, Filip;
    • Subbiah, Vivek;
    • Piha-Paul, Sarina A.;
    • Fu, Siqing;
    • Hess, Kenneth;
    • Roy-Chowdhuri, Sinchita;
    • Moulder, Stacy;
    • Gonzalez-Angulo, Ana M.;
    • Meric-Bernstam, Funda;
    • Hong, David S.
    Publication type:
    Article
    39
    40

    Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.

    Published in:
    Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36399-y
    By:
    • Harding, James J.;
    • Piha-Paul, Sarina A.;
    • Shah, Ronak H.;
    • Murphy, Jessica J.;
    • Cleary, James M.;
    • Shapiro, Geoffrey I.;
    • Quinn, David I.;
    • Braña, Irene;
    • Moreno, Victor;
    • Borad, Mitesh;
    • Loi, Sherene;
    • Spanggaard, Iben;
    • Park, Haeseong;
    • Ford, James M.;
    • Arnedos, Mónica;
    • Stemmer, Salomon M.;
    • de la Fouchardiere, Christelle;
    • Fountzilas, Christos;
    • Zhang, Jie;
    • DiPrimeo, Daniel
    Publication type:
    Article
    41

    Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers.

    Published in:
    Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-36399-y
    By:
    • Harding, James J.;
    • Piha-Paul, Sarina A.;
    • Shah, Ronak H.;
    • Murphy, Jessica J.;
    • Cleary, James M.;
    • Shapiro, Geoffrey I.;
    • Quinn, David I.;
    • Braña, Irene;
    • Moreno, Victor;
    • Borad, Mitesh;
    • Loi, Sherene;
    • Spanggaard, Iben;
    • Park, Haeseong;
    • Ford, James M.;
    • Arnedos, Mónica;
    • Stemmer, Salomon M.;
    • de la Fouchardiere, Christelle;
    • Fountzilas, Christos;
    • Zhang, Jie;
    • DiPrimeo, Daniel
    Publication type:
    Article
    42

    AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer.

    Published in:
    Science Translational Medicine, 2015, v. 7, n. 314, p. 1, doi. 10.1126/scitranslmed.aac5272
    By:
    • Hong, David;
    • Kurzrock, Razelle;
    • Youngsoo Kim;
    • Woessner, Richard;
    • Younes, Anas;
    • Nemunaitis, John;
    • Fowler, Nathan;
    • Tianyuan Zhou;
    • Schmidt, Joanna;
    • Minji Jo;
    • Lee, Samantha J.;
    • Mason Yamashita;
    • Hughes, Steven G.;
    • Fayad, Luis;
    • Piha-Paul, Sarina;
    • Nadella, Murali V. P.;
    • Mohseni, Morvarid;
    • Lawson, Deborah;
    • Reimer, Corinne;
    • Blakey, David C.
    Publication type:
    Article
    43

    Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.

    Published in:
    PLoS ONE, 2017, v. 12, n. 12, p. 1, doi. 10.1371/journal.pone.0189848
    By:
    • O’Neil, Bert H.;
    • Wallmark, John M.;
    • Lorente, David;
    • Elez, Elena;
    • Raimbourg, Judith;
    • Gomez-Roca, Carlos;
    • Ejadi, Samuel;
    • Piha-Paul, Sarina A.;
    • Stein, Mark N.;
    • Abdul Razak, Albiruni R.;
    • Dotti, Katia;
    • Santoro, Armando;
    • Cohen, Roger B.;
    • Gould, Marlena;
    • Saraf, Sanatan;
    • Stein, Karen;
    • Han, Sae-Won
    Publication type:
    Article
    44
    45
    46
    47
    48
    49
    50